Study of Fluorescence Spectroscopy Guided Optical Biopsy Needle for Prostate Cancer Diagnosis-2017-04-19

Event Information
Event Name: 
Study of Fluorescence Spectroscopy Guided Optical Biopsy Needle for Prostate Cancer Diagnosis
Event Date: 
04/19/2017 - 7:30pm
Event Location: 
Room M-114, Stanford University Medical School
Event Details
Event Type: 
Event Details: 

Wednesday, April 19, 2017, 7:30 PM

Location: Room M-114, Stanford University Medical School
Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations, self-serve)
Parking is usually free after 5 PM at Roth Way Garage, which is at the corner of Roth Way and Campus Drive West (E-7) on the map. The Stanford Hospital Cafeteria is near the Emergency entrance, at D-6 on the map. The Medical School is across Campus Drive West from Roth Way Garage, and Room M114 is accessible from outside the building at E-6 on the map.

SPEAKER: Amir Tehrani
Chief Executive Officer
Precision Biopsy, LLC

Study of Fluorescence Spectroscopy Guided Optical Biopsy Needle for Prostate Cancer Diagnosis

ABSTRACT: Current prostate biopsy cores have a very low diagnostic yield. These biopsies often fail to diagnose prostate cancer since 90% of cores are histopathologically classified as benign. The concentrations of endogenous fluorophores in prostate tissue vary with disease states. Thus, fluorescence spectroscopy could be utilized to quantify these variations for identification of malignant lesions. We investigated clinical feasibility of a 14 gauge (1.98 mm) optical biopsy needle guided by fluorescence spectroscopy for real-time in vivo prostate cancer diagnosis. Built-in optical sensor has 8x100µm fibers for tissue excitation and a single 200µm fiber to collect spectral data. Custom-made fluorometer has 2 light-emitting diodes at 290 and 340 nm and a spectrometer. User interface for fluorometer operation and data collection was developed using LabView software. Each spectral data acquisition required ~2 seconds. The in vivo biopsies were performed during radical retropubic prostatectomy surgery on the exposed prostate with blood flow to the gland intact. A tissue biopsy core was obtained from each biopsy site after acquisition of spectral data. Above procedure was repeated ex vivo after surgical excision of the prostate. Biopsy cores were histopathologically classified as either benign or malignant and correlated with corresponding spectral data. Partial Least Square analysis was performed to determine diagnostically significant principal components as potential classifiers. A linear support vector machine and leaveone-out cross validation method was employed for tissue classification. Thirteen patients were consented to the study. Histopathological analysis found cancer in 29/208 in vivo and 51/224 ex vivo viable biopsy cores. Study results show 72% sensitivity, 66% specificity, and 93% negative predictive value for in vivo and 75%, 80%, and 93%, respectively, for ex vivo malignant versus benign prostatic tissue classification. Optical biopsy needle has a very high negative predictive value to indicate benign tissue while sufficient sensitivity for targeting areas suspicious for cancer within the prostate gland. Hence, the optical biopsy needle can increase the diagnostic yield of prostate biopsies with consequent improvement in patient care.

BIOGRAPHY: Precision Biopsy is led by CEO Amir Tehrani, who has over 20 years’ of experience in management and operations, strategy, business development, marketing, design and development for Fortune 500 and start-up medical device companies. Prior to Precision Biopsy, Amir was the President and CEO of Amaranth Medical, Inc., a bioabsorbable stent company. He has been instrumental in the formation and financing of several medical device companies, including Inspiration Medical, Inc., Corventis, Inc. (acquired by Medtronic, Inc.), Spinal Modulation, Inc., (acquired by St. Jude Medical), Sonitus Medical, Inc., and RODO Medical, Inc. Amir also led successful investments and acquisition in the medical technology sector at Guidant Compass Group. He also held several leading marketing and engineering positions at Guidant Vascular Intervention, St. Jude Medial CRM Division, Ventritex, Inc., (acquired by St. Jude Medical), and MiniMed, Inc. (acquired by Medtronic, Inc.). Amir holds a BS in Electrical Engineering from the University of Idaho and an MS in Biomedical Engineering from California State University in Sacramento, CA.